We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: obesity
MedXY News
EnglishTag

obesity

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Preserving Bone Quality in Older Adults with Obesity Through Lifestyle Intervention: Insights from the LIMB-Q Trial
Diabetes & Endocrinologylifestyle interventionobesity

Preserving Bone Quality in Older Adults with Obesity Through Lifestyle Intervention: Insights from the LIMB-Q Trial

By MedXY|Oct 6, 2025

The LIMB-Q trial demonstrates that intensive lifestyle interventions combining weight management and exercise preserve bone quality in older adults with obesity, despite significant weight loss, highlighting a promising approach for mitigat

From Plate to Progress: Five Scientifically Proven Diets to Help Manage Obesity Effectively
Family Medicine & NutritiondietHealthy Eating

From Plate to Progress: Five Scientifically Proven Diets to Help Manage Obesity Effectively

By MedXY|Oct 8, 2025

Explore five scientifically supported dietary patterns that aid effective weight loss for individuals struggling with obesity, emphasizing balanced nutrition and sustainable lifestyle changes.

Time-Restricted Eating in Overweight Adults: Effects on Sleep, Mood, and Quality of Life Remain Neutral
Clinical Updatesmoodobesity

Time-Restricted Eating in Overweight Adults: Effects on Sleep, Mood, and Quality of Life Remain Neutral

By MedXY|Oct 8, 2025

A randomized clinical trial found that different timing schedules of an 8-hour time-restricted eating window combined with Mediterranean diet education did not significantly affect sleep, mood, or quality of life in adults with overweight o

Tirzepatide’s Efficacy in HFpEF and Obesity: Unraveling Diabetes’ Influence from the SUMMIT Trial
Cardiologyheart failure with preserved ejection fractionobesity

Tirzepatide’s Efficacy in HFpEF and Obesity: Unraveling Diabetes’ Influence from the SUMMIT Trial

By MedXY|Oct 8, 2025

The SUMMIT trial reveals that tirzepatide improves heart failure outcomes and quality of life in obese HFpEF patients with or without type 2 diabetes, despite attenuated weight loss in diabetic patients.

Orforglipron: A Promising Oral Small-Molecule GLP-1 Receptor Agonist for Early Type 2 Diabetes and Obesity Management
Clinical UpdatesGLP-1 receptor agonistobesity

Orforglipron: A Promising Oral Small-Molecule GLP-1 Receptor Agonist for Early Type 2 Diabetes and Obesity Management

By MedXY|Oct 8, 2025

Orforglipron demonstrates significant glycemic control and weight reduction benefits in early type 2 diabetes and obesity, with favorable safety and oral administration convenience.

Oral Semaglutide 25 mg: A New Oral Therapeutic Option for Weight Management in Overweight and Obese Adults
Diabetes & Endocrinologyclinical trialobesity

Oral Semaglutide 25 mg: A New Oral Therapeutic Option for Weight Management in Overweight and Obese Adults

By MedXY|Oct 8, 2025

Oral semaglutide 25 mg once daily significantly reduces body weight versus placebo and improves physical function in adults with overweight or obesity, offering an alternative to injectable formulations.

Early Insulin Sensitization by Tirzepatide in Japanese Patients with Obesity and Type 2 Diabetes: Insights from a Hyperinsulinaemic-Euglycaemic Clamp Study
Clinical Updatesinsulin sensitivityobesity

Early Insulin Sensitization by Tirzepatide in Japanese Patients with Obesity and Type 2 Diabetes: Insights from a Hyperinsulinaemic-Euglycaemic Clamp Study

By MedXY|Oct 8, 2025

A 12-week prospective study demonstrates tirzepatide significantly improves insulin sensitivity in obese Japanese patients with type 2 diabetes, independent of weight loss, as assessed by hyperinsulinaemic-euglycaemic clamp.

Optimizing Metabolic and Physical Health in Obese Older Adults: Impact of Exercise Modalities on Insulin Secretion, CNTF, and IGF-1 During Weight Loss
Clinical UpdatesCNTFIGF-1

Optimizing Metabolic and Physical Health in Obese Older Adults: Impact of Exercise Modalities on Insulin Secretion, CNTF, and IGF-1 During Weight Loss

By MedXY|Oct 8, 2025

Combining aerobic and resistance exercise with diet-induced weight loss in obese older adults significantly improves insulin secretion, preserves CNTFRα levels, and increases IGF-1, enhancing metabolic and physical function.

Synergistic Effects of Combined Aerobic and Resistance Exercise with Diet on Insulin Secretion and Neurotrophic Factors in Older Adults with Obesity
Clinical Updatesaerobic exerciseCNTF

Synergistic Effects of Combined Aerobic and Resistance Exercise with Diet on Insulin Secretion and Neurotrophic Factors in Older Adults with Obesity

By MedXY|Oct 8, 2025

Combining aerobic and resistance exercise with diet-induced weight loss in older adults with obesity significantly improves insulin secretion, metabolic health, and physical function, likely mediated by ciliary neurotrophic factor receptor

Dose-Dependent Enhancement of L-Tryptophan-Induced Gut Hormone Secretion and Appetite Suppression by Intraduodenal Calcium in Obesity
Clinical Updatescalciumobesity

Dose-Dependent Enhancement of L-Tryptophan-Induced Gut Hormone Secretion and Appetite Suppression by Intraduodenal Calcium in Obesity

By MedXY|Oct 8, 2025

Intraduodenal calcium at doses up to 1000 mg amplifies the anorexigenic effects of L-tryptophan by boosting gut hormones CCK, GLP-1, and PYY, reducing energy intake in obese males, highlighting a novel adjunctive approach for appetite regul

Enhanced Therapeutic Outcomes in Overweight/Obese Women with PCOS: Combining Metformin and Semaglutide
Clinical Updatesmetforminobesity

Enhanced Therapeutic Outcomes in Overweight/Obese Women with PCOS: Combining Metformin and Semaglutide

By MedXY|Oct 7, 2025

Combination therapy with metformin and semaglutide improves weight loss, metabolic parameters, menstrual function, and natural pregnancy rates in overweight/obese women with PCOS compared to metformin alone.

Impact of Diabetes and Obesity on Early Rhythm Control Outcomes in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial
Cardiologyatrial fibrillationdiabetes

Impact of Diabetes and Obesity on Early Rhythm Control Outcomes in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial

By MedXY|Oct 7, 2025

A secondary analysis of the EAST-AFNET 4 trial shows early rhythm control therapy effectively reduces cardiovascular events in atrial fibrillation patients regardless of diabetes status or obesity, supporting its broad clinical use.

Cagrilintide-Semaglutide Combination Shows Promising Efficacy for Weight and Glycemic Control in Adults with Type 2 Diabetes and Obesity
Diabetes & Endocrinologycagrilintideobesity

Cagrilintide-Semaglutide Combination Shows Promising Efficacy for Weight and Glycemic Control in Adults with Type 2 Diabetes and Obesity

By MedXY|Oct 6, 2025

A 68-week phase 3a trial demonstrates that once-weekly cagrilintide-semaglutide significantly reduces body weight and improves glycemic control compared to placebo in adults with overweight or obesity and type 2 diabetes, with good tolerabi

Once-Weekly Semaglutide 2.4 mg for Obesity Management in Asian Adults: Efficacy, Safety, and Policy Insights from the STEP 11 Trial
Diabetes & EndocrinologyAsian PopulationBMI

Once-Weekly Semaglutide 2.4 mg for Obesity Management in Asian Adults: Efficacy, Safety, and Policy Insights from the STEP 11 Trial

By MedXY|Oct 6, 2025

The STEP 11 trial demonstrates that once-weekly semaglutide 2.4 mg significantly reduces bodyweight in Asian adults with obesity (BMI ≥25 kg/m²), supporting its safety and guideline inclusion in these populations with unique BMI thresholds.

Injectable GLP-1 Use Soars Among US Adults with Diabetes: Trends and Clinical Implications
Clinical Updatesdiabetes managementGLP-1 receptor agonists

Injectable GLP-1 Use Soars Among US Adults with Diabetes: Trends and Clinical Implications

By MedXY|Oct 6, 2025

Nearly 1 in 4 US adults with diabetes used injectable GLP-1 receptor agonists in 2024, reflecting rising adoption for glycemic control and obesity management with notable demographic disparities.

The Hidden Battle in Our Brain: Why We Can’t Resist Hedonic Eating
Family Medicine & NutritiondopamineGLP-1 receptor

The Hidden Battle in Our Brain: Why We Can’t Resist Hedonic Eating

By MedXY|Oct 5, 2025

Discover how dopamine neurons in the brain’s reward center overpower satiety signals, driving hedonic eating even when we’re full, revealing new insights for obesity treatment.

GLP-1 Receptor Agonists in Obesity: Emerging Evidence for Cancer Risk Modulation
Clinical Updatescancer riskGLP-1 receptor agonists

GLP-1 Receptor Agonists in Obesity: Emerging Evidence for Cancer Risk Modulation

By MedXY|Aug 31, 2025

GLP-1 receptor agonists, used for obesity and type 2 diabetes management, are linked to a 17% lower overall cancer risk, notably hormone-sensitive cancers, but may increase kidney cancer risk. Further research is needed to clarify safety an

Epicardial Adipose Tissue as a Predictor of New-Onset Atrial Fibrillation: Insights from a Danish Population Cohort
Cardiologyatrial fibrillationCardiovascular risk factors

Epicardial Adipose Tissue as a Predictor of New-Onset Atrial Fibrillation: Insights from a Danish Population Cohort

By MedXY|Oct 5, 2025

This Danish cohort study demonstrates that increased epicardial adipose tissue volume independently elevates the risk of new-onset atrial fibrillation, highlighting the importance of fat distribution beyond BMI in cardiovascular risk assess

Tirzepatide Enhances Quality of Life in Adults with Obesity or Overweight: Insights from the SURMOUNT-3 Trial
Diabetes & Endocrinologyobesityquality of life

Tirzepatide Enhances Quality of Life in Adults with Obesity or Overweight: Insights from the SURMOUNT-3 Trial

By MedXY|Oct 5, 2025

Tirzepatide significantly improves health-related quality of life alongside weight reduction in adults with obesity or overweight, especially those experiencing physical function limitations, according to SURMOUNT-3 trial results.

Tirzepatide Significantly Lowers Predicted 10-Year Type 2 Diabetes Risk in Chinese Adults with Overweight or Obesity: Insights from the SURMOUNT-CN Trial
Diabetes & EndocrinologyChinese Populationobesity

Tirzepatide Significantly Lowers Predicted 10-Year Type 2 Diabetes Risk in Chinese Adults with Overweight or Obesity: Insights from the SURMOUNT-CN Trial

By MedXY|Oct 5, 2025

Post hoc analysis of the SURMOUNT-CN trial shows tirzepatide markedly reduces the 10-year predicted risk of type 2 diabetes in Chinese individuals with overweight or obesity, regardless of baseline BMI or prediabetes status.

Prev
5 / 7
1…34567
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities